Vivasc Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Vivasc Therapeutics's estimated annual revenue is currently $201k per year.
- Vivasc Therapeutics's estimated revenue per employee is $100,500
Employee Data
- Vivasc Therapeutics has 2 Employees.
- Vivasc Therapeutics grew their employee count by 0% last year.
Vivasc Therapeutics's People
| Name | Title | Email/Phone |
|---|
Vivasc Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $43.2M | 215 | 6% | N/A | N/A |
#2 | $81.8M | 407 | 10% | N/A | N/A |
#3 | $11.7M | 58 | 0% | N/A | N/A |
#4 | $1011.8M | 5034 | -9% | N/A | N/A |
#5 | $44.8M | 223 | 1% | N/A | N/A |
#6 | $13.1M | 65 | 5% | N/A | N/A |
#7 | $16.5M | 82 | 41% | N/A | N/A |
#8 | $17.3M | 86 | -5% | N/A | N/A |
#9 | $67.9M | 338 | 23% | N/A | N/A |
#10 | $14.9M | 74 | 7% | N/A | N/A |
What Is Vivasc Therapeutics?
Vivasc Therapeutics is an early stage, pre-clinical cardiac drug development company. We are utilizing the proprietary Cardiac Targeting Peptide (CTP) platform technology to deliver various cargo exclusively to cardiomyocytes in a non-invasive manner. We are actively seeking: Joint development partners for our lead compound, CTP-amio, for the treatment of arrhythmias (atrial fibrillation and ventricular tachycardia) Partners to use CTP as a platform vector to deliver other therapeutic cargo (oligonucleotides, peptides, proteins, drugs, nanoparticles, stem cell therapies, etc.) exclusively to cardiomyocytes
keywords:N/A
N/A
Total Funding
2
Number of Employees
$201k
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Pittsburgh
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.1M | 2 | -33% | N/A |
#2 | N/A | 2 | -94% | N/A |
#3 | $0.1M | 2 | 0% | N/A |
#4 | $0.2M | 2 | -33% | N/A |
#5 | $7.5M | 2 | -33% | N/A |